COVID-19: AstraZeneca CEO on long-term protection from jab

The boss of pharmaceutical giant AstraZeneca says its coronavirus vaccine – developed with Oxford University – may have played a key role in reducing Covid-related hospitalisations in the UK.

Pascal Soriot said his company’s vaccine promoted a greater T-cell [part of the immune system which defends the body against specific infections] response in older people than some others.

Mr Soriot was speaking to the Today programme ahead of the formal opening of AstraZeneca’s new science lab in Cambridge.